{"links":{"feed":"https://www.erudio.com/reports/start-001-nct05592626/feed.json","html":"https://www.erudio.com/reports/start-001-nct05592626","json":"https://www.erudio.com/reports/start-001-nct05592626.json","markdown":"https://www.erudio.com/reports/start-001-nct05592626.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"start-001-nct05592626"}},"request":"https://www.erudio.com/contact?report=start-001-nct05592626"},"offer":{"cited_clinicians":5,"cited_commentary_sources":18,"verified_hcp_statements":66,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":8},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"start-001-nct05592626"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=start-001-nct05592626","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/start-001-nct05592626","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 66 verified statements · 40 from 5 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T15:05:08.832382Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":1},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":5,"title":"Primary endpoint: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)"},{"claim_count":15,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":12,"title":"Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)"},{"claim_count":8,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":13,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":10,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T8","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":8,"coverage":"discussed","id":"A1","source_count":4,"title":"Selective signaling and biological dose selection"},{"claim_count":6,"coverage":"discussed","id":"A2","source_count":4,"title":"Baseline predictors and treatment-induced immune changes"},{"claim_count":6,"coverage":"discussed","id":"A3","source_count":5,"title":"Research access, patient support and regulatory expectations"},{"claim_count":5,"coverage":"discussed","id":"A4","source_count":1,"title":"Anecdotal comparison with Anktiva in metastatic disease"},{"claim_count":15,"coverage":"discussed","id":"A5","source_count":3,"title":"Preclinical rationale and proposed immune reprogramming"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":15,"cited_clinicians":5,"cited_clinicians_by_role":{"physician":3,"physician, Gastroenterology":1,"physician, Medical oncology":1},"cited_physicians":5,"cited_sources":20,"claims_by_expression_type":{"comparison":10,"experience":2,"interpretation":29,"opinion":5,"primary_context":4,"question":3,"restatement":12,"uncertainty":1},"claims_by_kind":{"publication_statement":8,"source_observation":58},"clinician_statements":40,"evidence_units":69,"findings":7,"organisational_accounts":1,"people_cited":13,"people_identity_verified":8,"people_total":13,"screened_sources":52,"verified_claims":66},"findings_index":[{"cited_clinicians":4,"id":"F1","structure":{"claims":22,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":5,"views":16},"limitations":4,"links":{"context":1,"support":25},"ma_question":true,"named_voices":9,"passages":20,"sources":15,"sources_by_kind":{"commentary":10,"media":3,"publication":2}},"title":"START-001: what most speakers highlight in preliminary activity in refractory tumors","title_holders":{"cited_claim_ids":["claim-a4613ea747b6c9e7fa2c","claim-3552f9ffe56e465a66e0","claim-a44bcff167444815d75a","claim-3d0e2d7b5352ee9adc18","claim-1695af12cacb6c4a3a9e","claim-98adc90166e7b63f5d61","claim-ccd2d3c65477193f21cf","claim-7b1c2f23e635307617c4","claim-1bcbc31e79d18163463f","claim-eb6ed93e52a144d0e4fc","claim-57338e8bae6f52c749fe","claim-04041923c63f67b2f33c","claim-fd7791087490420fab54","claim-c78ef7c2309fe2c4cc5d"],"clinicians":false,"holders":8,"speakers":9,"view":"reading"},"evidence_line":"22 statements from 9 speakers in 15 sources, 3 of them podcasts or videos","holder_line":"8 of the 9 named speakers in this finding hold this view"},{"cited_clinicians":3,"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":5},"limitations":4,"links":{"context":0,"support":7},"ma_question":true,"named_voices":5,"passages":7,"sources":7,"sources_by_kind":{"commentary":4,"media":1,"publication":2}},"title":"Early transient AEs: what some clinicians highlight, but some speakers flag CRS risk","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-ccd2d3c65477193f21cf","claim-4f2638f15a6862ce4be1"],"clause":"some speakers flag CRS risk","holders":2},"cited_claim_ids":["claim-768c285250bdc2980ce1","claim-a2f9af6d9da8163d75bd"],"clinicians":true,"holders":2,"speakers":5,"view":"reading"},"evidence_line":"7 statements from 5 speakers in 7 sources, 1 of them a podcast or video","holder_line":"2 of the 5 named speakers in this finding hold this view, each a confirmed clinician; 2 of the 5 hold its caveat, “some speakers flag CRS risk”"},{"cited_clinicians":2,"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":0,"views":4},"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":4,"passages":8,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Trial access: what speakers say","evidence_line":"6 statements from 4 speakers in 6 sources"},{"cited_clinicians":4,"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":3,"views":3},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":4,"passages":9,"sources":6,"sources_by_kind":{"commentary":3,"media":1,"publication":2}},"title":"Immune-cold tumors: what speakers say","evidence_line":"8 statements from 4 speakers in 6 sources, 1 of them a podcast or video"},{"cited_clinicians":3,"id":"F5","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":6,"views":4},"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":4,"passages":13,"sources":6,"sources_by_kind":{"commentary":3,"media":1,"publication":2}},"title":"T-cell selectivity: what speakers stress; a clinician ties RP2D to expansion","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-e77bf2f40a15699dafb1"],"clause":"a clinician ties RP2D to expansion","holders":1},"cited_claim_ids":["claim-a66ff3e4f602bb2c50dc","claim-668bcb8cf5b71f01e6e8","claim-dcf4ad128d80d721dcbc","claim-e77bf2f40a15699dafb1","claim-14665b0cf28f653d2e72","claim-ac5fa3462724308945b0"],"clinicians":false,"holders":4,"speakers":4,"view":"reading"},"evidence_line":"11 statements from 4 speakers in 6 sources, 1 of them a podcast or video","holder_line":"4 of the 4 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician ties RP2D to expansion”"},{"cited_clinicians":0,"id":"F6","structure":{"claims":5,"claims_by_group":{"comparisons":2,"experience":1,"questions":0,"restated":1,"views":1},"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":3,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Invikafusp alfa: why a speaker favors it on a hunch and a scan example","title_holders":{"cited_claim_ids":["claim-7e69a68b69f50ad24e28","claim-220a40e8b7979bee5346","claim-8ea0e9805dc3486d7ed2"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"5 statements from 2 speakers in 1 source","holder_line":"1 of the 2 named speakers in this finding holds this view"},{"cited_clinicians":2,"id":"F7","population":"beyond","structure":{"claims":15,"claims_by_group":{"comparisons":7,"experience":0,"questions":0,"restated":1,"views":7},"limitations":4,"links":{"context":0,"support":19},"ma_question":true,"named_voices":2,"passages":19,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Preclinical T-cell reprogramming: why a clinician supports clinical testing","title_holders":{"cited_claim_ids":["claim-38e6139f8c6d1328ee20"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"15 statements from 2 speakers in 3 sources","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers see clinical promise in selected refractory-disease settings"},{"id":"section-2","level":2,"title":"Speakers describe manageable toxicity without dismissing CRS"},{"id":"section-3","level":2,"title":"Speakers welcome research access; an X referral exchange blurs it with approval"},{"id":"section-4","level":2,"title":"An X exchange asks what distinguishes responders before and during treatment"},{"id":"section-5","level":2,"title":"Speakers emphasize selective signaling; one interprets dose choice through pharmacodynamics"},{"id":"section-6","level":2,"title":"One X account favors Invika over Anktiva on an explicitly personal hunch"},{"id":"section-7","level":2,"title":"Beyond the trial population"},{"id":"section-8","level":3,"title":"One speaker presents preclinical reprogramming as a rationale, not proof of human advantage"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F5","shared_claims":1}],"id":"T1","label":"Primary endpoint: Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":5}],"id":"T2","label":"Primary endpoint: Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)"},{"findings":[{"id":"F1","shared_claims":15},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T3","label":"Primary endpoint: Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":12},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":1}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":5}],"id":"T7","label":"Safety and tolerability"},{"findings":[],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T15:05:08.832382Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T17:33:37Z","record_hash":"7cb658f18b431d75495f084bed7eba59d680bc6ee543c5fd892605cbb84e6f36","release_hash":"e2024c46f4598f6ec53a03ed10612732e9b12ba4349af392bdfaf5bcb0537c28","report_id":"erudio-nct05592626","run_id":"b0966444-847e-467f-862a-e1591beae346","schema_version":"5.0","slug":"start-001-nct05592626","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A physician reads START-001 favorably because of activity after checkpoint-inhibitor failure, but stresses that the evidence is preliminary. A speaker's stronger endorsement concerns TMB-high colorectal cancer without liver metastases; another cautions against treating activity as established benefit, citing small numbers. Cytokine-release syndrome remains a concern in the discussion. Durability is unresolved, and results from different dose and biomarker groups cannot be treated as a single response estimate.","examples":[],"meta_description":"52 sources screened · 66 verified statements (40 from clinicians verified by NPI or staff page) from 20 sources · 7 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T17:33:37Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":52},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","33 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 25 sources about other trials or topics are not included.","Repeated posts, reposts, presentation summaries and near-identical interview extracts should not be counted as independent HCP assessments.","Several favorable views come from people described by their sources as involved in START-001 or STAR0602 development; those descriptions do not establish independent external endorsement.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The accounts use different phases, dose subsets, biomarker groups and outcome definitions. Percentages cannot be pooled, and target-lesion regression must not be relabeled as objective response or disease control.","Small patient numbers and uncertain durability limit the strength of the clinical-benefit interpretation, even where speakers are enthusiastic.","No trial protocol or matching regulatory label was available in the reviewed material. Detailed supportive-care rules and the X exchange's FDA-approval assertion could not be independently checked.","The access and referral statements are dated experiences, not confirmation of current site availability or individual eligibility. A speaker's cancer type is not stated."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":2,"registry":0,"regulatory":0,"x_thread":15,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":18,"context":2},"count":20,"evidence_window":{"end":"2026-10-31","start":"2022-11-10"},"retrieval_snapshot":"2026-11-19T13:42:06.967361Z","timeline":[{"count":2,"week":"2022-W45"},{"count":1,"week":"2023-W49"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2025-W06"},{"count":3,"week":"2025-W27"},{"count":1,"week":"2025-W45"},{"count":2,"week":"2025-W46"},{"count":1,"week":"2025-W48"},{"count":4,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT05592626:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05592626:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42386344","quote_policy":"short_quote_link_out"},{"id":"pubmed:42919963","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hvybly7ak5rfumcoeda5r4mx-3ln2mhizzhc2b","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7519378577084256256","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7519433612430172162","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1585995344810123265:9a57f29b-37ae-4dc6-af34-abe3e7fa6465","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1590525908536164353:505810b2-dba2-4c97-aceb-16f6534c1e9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1590544141481816064:957643d4-f3f2-4c55-ac43-9d2da24f4faa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1618958858516582401:202f0672-553f-4883-82d9-c84d09e233a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1618960299444559875:ece21d81-0cc6-44a2-b40b-59e73e1703cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1620557772709404672:3b1abe8e-2420-4456-971a-daeca7c80cd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1621554226844368897:29da5832-a96e-4190-bc45-6774b343ef4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1633981447584333824:6d8689b4-102d-457b-b18a-e513f2e1dbd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665435916591157248:fc2065d9-d577-4eda-8d35-963232bb082e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1666147992804392978:39394aab-7c4a-4c71-98e5-200e5642f898","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1673789609032003585:5db79775-cbd8-47ba-9ebc-8334a4a0f6d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1731494467301945619:613d4772-6156-4bc8-8b27-722bec2b391a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1855309378208866755:76630da0-5a04-4228-aec7-fd4ac2a7eeb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1856011577469595866:0962757b-48e1-4da9-80ba-8a3949ac02a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1862632761971851633:432b4419-e4b0-45ba-8875-c53ded6322e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1870845229613343175:ed2de285-a3cb-4afb-b46e-d8dadaaaf509","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1870846767811428510:2465aaf3-0dce-4ea9-a41f-6bd5442a4de6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1879952089893282126:827f4b61-f0f3-435e-a036-90f912939d28","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1886973218923405327:706d239a-39e2-44f6-97d9-b48a2433e720","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1913062532631191998:993e77ef-347b-4fcf-a361-aaffd8e635bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1917036168748929302:5f8a4397-bb13-4a03-88de-6be450ee3e80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1921849075030503876:6f400429-2f3a-43f6-a948-164ba76ba1d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1927591019123536097:524aae56-bffa-4d0d-bb22-d1c441713b8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928572289148129345:07ea7669-cf2e-4c3d-a950-333dcde83426","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940420799925477594:340e1b83-ebeb-47df-b500-6e6721a8d0f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940421044449292299:33a9cd20-b4b1-45ed-8193-4f769bbfbb04","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940421111248048207:4553bf76-c2af-47dd-94fe-25b6d595cccc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940514795113116107:03a46130-6cd5-4bf2-b9b5-25ae890fb939","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940626650154045463:f2618170-b7d3-425c-b8b0-ee7ad8e7a66d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1941270466800619979:9be8e7a5-ab04-4249-b0f6-4e6852f945a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1941270969081122892:284816b5-bdcf-4379-8e42-4f9e491a2077","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1941613570325872850:9e6e177d-7329-4e1a-a3ae-3fae6493e25c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1972735315598340162:f8428b26-cccf-4133-a77f-97bf6a57dc7e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1972805388052390122:78c37dfc-be08-4720-b612-63f417cb2a34","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979861728134377847:a9f9b444-2653-44a1-9b07-bc3a3b10122e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986848924355670066:63462238-ab32-4818-b151-a6a6acbf2b5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113610916767965649:9740532b-2f49-4061-89de-a897fdad413c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113626128741007432:c7c6d5c5-6b32-4444-ad13-c1cbc8109347","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113668301759057962:da5b8107-dc54-421f-8b7b-f0fd4ccb4899","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113778018347028794:c5406109-f2bd-4ebc-bb11-192795a67cb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114034283186639086:5bbd4863-701c-4611-9614-84ad05344170","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114104818033713573:0824e7a2-8555-413c-a198-3a22a150a855","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114207676184039862:b606fb69-7bb6-440f-8340-31d0c6044bfa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116141689244958907:3f3bb08a-65b3-449d-a61b-85702f9c35ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116319237606363580:abc04d8d-6043-4810-a82e-231e61da7753","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116375387681005793:bcbae4e9-f86d-4644-9047-7d8303b5cd5b","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FsuyKDTRxCY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:RNd4VJ5dh6s","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:q9FnWwOfhUw","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":46,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":52},"count":52,"evidence_window":{"end":"2026-10-31","start":"2022-10-28"},"retrieval_snapshot":"2026-11-19T13:42:06.967361Z","timeline":[{"count":1,"week":"2022-W43"},{"count":2,"week":"2022-W45"},{"count":2,"week":"2023-W04"},{"count":2,"week":"2023-W05"},{"count":1,"week":"2023-W10"},{"count":1,"week":"2023-W22"},{"count":1,"week":"2023-W23"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W49"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2024-W48"},{"count":2,"week":"2024-W51"},{"count":2,"week":"2025-W03"},{"count":1,"week":"2025-W06"},{"count":2,"week":"2025-W16"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W20"},{"count":2,"week":"2025-W22"},{"count":8,"week":"2025-W27"},{"count":2,"week":"2025-W40"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W45"},{"count":2,"week":"2025-W46"},{"count":1,"week":"2025-W48"},{"count":9,"week":"2026-W43"},{"count":3,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":8,"registry":0,"regulatory":0,"x_thread":48,"x_video":0,"youtube":10}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"invikafusp alfa","slug":"invikafusp-alfa"},{"brand_names":["Camptosar"],"label":"irinotecan","slug":"irinotecan"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"},{"reason":"Unmapped registry condition: Genital Neoplasm, Female","status":"unmapped"},{"reason":"Unmapped registry condition: Urogenital Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Lung Neoplasm","status":"unmapped"},{"reason":"Unmapped registry condition: Neoplasms by Site","status":"unmapped"},{"reason":"Unmapped registry condition: Papillomavirus Infection","status":"unmapped"},{"reason":"Unmapped registry condition: Epstein-Barr Virus Infections","status":"unmapped"},{"reason":"Unmapped registry condition: Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Vulvar Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Vulvar Diseases","status":"unmapped"},{"reason":"Unmapped registry condition: Abdominal Neoplasm","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"START-001","aliases":["START-001","A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)"],"brief_title":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Advanced Solid Tumors","Genital Neoplasm, Female","Urogenital Neoplasms","Lung Neoplasm","Neoplasms by Site","Papillomavirus Infection","Epstein-Barr Virus Infections","Carcinoma","Neoplasms","Vulvar Neoplasms","Vulvar Diseases","Abdominal Neoplasm","NSCLC (Non-small Cell Lung Cancer)","Colorectal Cancer"],"display_condition":"antigen-rich advanced solid tumors","display_interventions":[["invikafusp alfa (STAR0602)"],["invikafusp alfa (STAR0602)","irinotecan"],["invikafusp alfa (STAR0602)","docetaxel"]],"enrollment":{"count":366,"type":"ESTIMATED"},"interventions":[{"name":"STAR0602","synonyms":["Invikafusp alfa"],"type":"DRUG"},{"name":"Irinotecan (Camptosar)","synonyms":["Camptosar"],"type":"COMBINATION_PRODUCT"},{"name":"Docetaxel (Taxotere)","synonyms":["Taxotere"],"type":"COMBINATION_PRODUCT"}],"nct_id":"NCT05592626","official_title":"A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-09","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1","timeFrame":"Cycle 1 (Cycle length= 28 days)"},{"measure":"Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to 3 years"},{"description":"Complete response (CR) and partial response (PR)","measure":"Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)","timeFrame":"Up to 3 years"}],"registered_date":{"date":"2022-10-24","type":"ACTUAL"},"registry_last_updated":"2026-08-11","registry_url":"https://clinicaltrials.gov/study/NCT05592626","short_name":"START-001","short_name_basis":"registry_acronym","sponsor":"Marengo Therapeutics, Inc.","start_date":{"date":"2023-01-04","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase1, phase2","study_ids":[{"id":"CP-START-001","type":"sponsor_study_id"},{"id":"2023-505334-10-01","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}